NMN is phosphorylated to NAD+ via NMN adenylyltransferase (NMNAT). Bypasses rate-limiting NAMPT enzyme step used by NR pathway. Raises tissue and serum NAD+ levels. Activates sirtuins (SIRT1–7), PARP DNA repair enzymes, and CD38.
Studies have administered: 250–1000mg/day oral in human trials; 125–500mg/day in Japanese safety/efficacy studies
Yoshino (2021) NEJM paper: 250mg/day NMN restored muscle NAD+ and improved insulin sensitivity in postmenopausal women. Multiple human trials 2020–2024 confirm NAD+ elevation. Aging hallmark improvements in multiple model organisms.
Generally well-tolerated across human trials; flushing less common than niacin; long-term safety data accumulating
These compounds have been examined together in research literature. Combination use is not endorsed or recommended — this information is provided for research context only.
Want a Complete Research Monograph?
Our AI can generate a 2,000+ word deep-dive on NMN (Nicotinamide Mononucleotide) — including full clinical trial summaries, pharmacokinetics, and research frontiers.
Generate Deep Dive in Research Chat